Observed irAEs in patients who developed CPI related nephrotoxcity and their outcome

Patient #CPIAKI severityAssosciated irAERelation to AKI diagnosisRenal and non renal irAE outcome
11NivolumabNephrotic syndromeHypothyrodisim (G2)4 weeks prior to AKIPersistent hypothyrodisimComplete remission of nephrotic syndrome
14PembrolizumabG3Colitis (G3)2 weeks prior to AKIDiarrhea and renal function improved partially then patient developed 2nd AKI
2NivolumabG3Elevated dsDNA and RNP titersAt the time of AKI diagnosisTiters became undetectable after 4 weekPartial renal recovery
6NivolumabG3Hypothyrodisim (G2)10 weeks prior to AKIPersistent hypothyrodisimComplete renal recovery
3NivolumabG3Myositis6 weeks after AKIMyosisits had resolvedPartial renal recovery
7TremelimumabG3Dermatitis (G1)Pneumonitis (G2)At the time of AKI diagnosisDermatitis and pneumonitis had resolved within 2 weekPartial renal recovery
15NivolumabG1Hypothyrodisim (G2)Esophagitis (G2)5 weeks prior to AKIEsophagitis and AKI had fully recoveredPersistent hypothyrodisim
10PembrolizumabG3Dermatitis (G1)Pneumonitis (G2)At the time of AKI diagnosisDermatitis and pneumonitis had resolved within 1 weekPartial renal recovery
8Nivolumab and IpilimumabG3Dermatitis (G1)Thyroditis (G3)Adrenal insuffiency (G1)5 weeks prior to AKIPersistent hypothyrodisim and adrenal insuffiencyComplete renal recovery

Common Terminology Criteria for Adverse Events (CTCAE)

Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated

Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting ageappropriate instrumental ADL

Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL

Grade 4 Life-threatening consequences; urgent intervention indicated

CPI immue Checkpoint inhibitor, AKI acute kidney injury, irAE immue related adverse events